The return of public FDA Advisory Committee (AdCom) meetings provides crucial transparency into the agency's thinking. Despite hopes for a more lenient FDA after recent high-profile departures, the critical tone in recent AdComs indicates the agency is not "pulling punches" and maintains a high bar for approval.

Despite significant layoffs and leadership changes early in the year that caused delays, the FDA dramatically increased its output, approving nearly twice as many drugs in the second half of 2025 as the first. This suggests the agency adapted and found a new, more efficient footing after an initial period of disruption.

While political drama at the top of the FDA captures headlines, the agency's rank-and-file reviewers are largely maintaining operational continuity. Many drug programs are still receiving necessary feedback within expected timeframes, suggesting the core machinery of the FDA is resilient.

Following the departure of commissioner Marty McCary, the FDA seems to be taking a more predictable stance. Several companies that previously received Complete Response Letters, such as Reflemunov and Outlook, are now successfully resubmitting their applications, signaling a potential thaw in industry-regulator relations.

A change in leadership at the FDA can completely alter the viability of a drug's approval. Unicure's gene therapy, previously stalled under former officials Marty Makkari and Vinay Prasad, found a clear path to submission after they departed. This demonstrates that the philosophies of individual regulators, not just established processes, can dictate a drug's future.

Despite widespread concern about political disruption at the FDA, key metrics for innovation in new drug approvals—such as first-in-class drugs and new targets—were almost completely flat in 2025 compared to previous years. This suggests the core regulatory engine has remained consistent, for now.

Following the exit of controversial CBER director Vinay Prasad, the FDA approved several drugs that might have struggled under his tenure. This suggests a potential shift towards more regulatory flexibility, possibly influenced by political pressure ahead of midterm elections, creating opportunities for sponsors with controversial applications.

Recent positive FDA decisions for Unicure and Regenexx are not arbitrary reversals. Instead, they represent the agency returning to its standard, pre-McCary/Prasad scientific and regulatory processes. This "reversion to the mean" suggests the agency is course-correcting after a period of unusual and disruptive leadership.

Despite political chaos, most FDA work continues. However, companies are experiencing severe inconsistency, with different agency groups offering contradictory advice and major rejections being walked back, as seen with Atara Biotherapeutics. This demonstrates how top-level instability creates unpredictable regulatory hurdles for developers.